IP Library Granted Patent US 7,404,965
Granted Patent B2
US 7,404,965 · App. 11/634,005 · Granted Jul 29, 2008

Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels

Assignee: Antares Pharma IPL AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,404,965
App. No.
11/634,005
Granted
Jul 29, 2008
Kind
B2
Abstract

A pharmaceutical composition in the form of a solution, cream, lotion, spray, ointment, gel, aerosol, tablet, suppository or patch device for transdermal or transmucosal administration of alprazolam to a subject, which includes as a permeation enhancing mixture a fatty component in an amount of 0.1% to 20% by weight which is one of (a) a saturated fatty alcohol of formula CH 3 —(CH 2 ) n —CH 2 OH, a saturated fatty acid of formula CH 3 —(CH 2 ) n —CH 2 COOH, (b) an unsaturated fatty alcohol of formula CH 3 (C n H 2(n−1) )—OH, or (c) a fatty acid of formula CH 3 (C n H 2(n−1) )—COOH, wherein n is an integer of between 8 and 22; and a vehicle that includes a C 1 -C 4 alkanol, a polyalcohol, and water.

Claims (15)

1. A pharmaceutical composition in the form of a solution, cream, lotion, spray, ointment, gel, aerosol, tablet, suppository or patch device for transdermal or transmucosal administration of alprazolam to a subject, comprising as a permeation enhancing mixture:

a fatty component in an amount of 0.1% to 20% by weight and comprising a saturated fatty alcohol of formula CH 3 —(CH 2 ) n —CH 2 OH, or an unsaturated fatty alcohol of formula CH 3 (C n H 2(n−1) )—OH, wherein n is an integer of between 8 and 22; and

a vehicle comprising a monoalkylether of diethyleneglycol, a C 1 -C 4 alkanol, a polyalcohol, and water.

2. The pharmaceutical composition of claim 1 , wherein the polyalcohol is a glycol, the alkanol is ethanol, and the monoalkylether of diethyleneglycol is diethylene glycol monoethylether.

3. The pharmaceutical composition of claim 1 wherein the vehicle comprises 5% to 75% by weight of a C 1 -C 4 alkanol, 0.5% to 50% of a polyalcohol, water, and up to 40% by weight of a monoalkylether of diethyleneglycol, with all weights calculated based on the total weight of the composition and provided that the total weights of the components does not exceed 100%.

4. The pharmaceutical composition of claim 3 , wherein the fatty component is present in an amount of 0.1% to 10%, the alkanol is present in an amount of 15% to 65%, the polyalcohol is present in an amount of 3% to 20%, and the monoalkylether of diethyleneglycol is present in an amount of 0.2% to 25%.

5. The pharmaceutical composition of claim 4 , wherein the fatty component is present in an amount of 0.2% to 3%, the alkanol is present in an amount of 20% to 55%, the polyalcohol is present in an amount of 4% to 10%, and the monoalkylether of diethyleneglycol is present in an amount of 2% to 8%.

6. The pharmaceutical composition of claim 1 , which further comprises a gelling agent in an amount of 0.2 to 3% by weight so that the composition is in the form of a gel.

7. The pharmaceutical composition of claim 6 , wherein the gelling agent is a polyacrylic acid or a cellulose compound.

8. The pharmaceutical composition of claim 7 , wherein the gelling agent is carbopol, hydroxypropylmethylcellulose, carboxymethylcellulose, ethylhydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, polyvinylpyrrolidone, a polyoxyethylene/polyoxypropylene copolymer, polyvinylalcohol, a natural gum, an alginate, or a pectin.

9. The pharmaceutical composition of claim 6 , which further comprises a pH regulator in an amount of 0.05% to 2% by weight.

10. The pharmaceutical composition of claim 9 , wherein the pH regulator is a tertiary amine or sodium hydroxide.

11. The pharmaceutical composition of claim 1 , wherein the fatty component is a saturated or unsaturated fatty alcohol where n is an integer of between 8 and 12, the polyalcohol is a glycol, the alkanol is ethanol, and the monoalkylether of diethyleneglycol is diethylene glycol monoethylether.

12. The pharmaceutical composition of claim 11 , wherein the fatty component is dodecanol, the polyalcohol is propylene glycol and the pH regulator is triethanolamine or tromethamine.

13. The pharmaceutical composition of claim 1 , which further comprises one or more of a flavor agent, saborizant, sweetener or solubilizant in an amount sufficient to impart desired properties to the composition.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2009
From: CARRARA, DARIO; PORTO, GABRIEL; RODRIGUEZ, JORGE
To: ANTARES PHARMA, IPL, AG
Reel/Frame 023419/0700 →
RELEASE OF SECURITY INTEREST Recorded Oct 13, 2009
From: MMV FINANCIAL INC.
To: ANTARES PHARMA, INC.
Reel/Frame 023355/0907 →
Priority Claims (1)
WO PCT/EP00/07533 · Aug 3, 2000 · international
Continuity (2)
Continuation 1034357000
Related Publication 20070098775A1 · May 3, 2007